Rxcelerate Limited is a registered limited company operating under Reg: 08284658, established in November 7th, 2012. Located at The Dorothy Hodgkin Building within the Babraham Research Campus of Cambridge, CB22 3FH, UK, RxCelerate focuses on providing outsourced drug discovery and development services to a global client base. The company operates as a leading provider specializing in comprehensive solutions spanning from initial research concepts through clinical candidate support. Rxcelerate’s core offerings include bespoke in silico design and discovery, antibody generation utilizing advanced techniques, synthetic chemistry expertise, and robust in vitro testing capabilities. They also manage preclinical services, including formulation development and animal studies. RxCelerate boasts a significant international presence with operations strategically positioned within Europe and North America. The company is structured as a leading provider of outsourced drug discovery and development, emphasizing project management to ensure seamless execution and client satisfaction. Rxcelerate’s skilled workforce ensures high standards across all services. RXCelerate's SIC codes include -72110: Research and experimental development on biotechnology, representing the core industry focus.

Rxcelerate Limited is a registered limited company operating under Reg: 08284658, established in November 7th, 2012. Located at The Dorothy Hodgkin Building within the Babraham Research Campus of Cambridge, CB22 3FH, UK, RxCelerate focuses on providing outsourced drug discovery and development services to a global client base. The company operates as a leading provider specializing in comprehensive solutions spanning from initial research concepts through clinical candidate support. Rxcelerate’s core offerings include bespoke in silico design and discovery, antibody generation utilizing advanced techniques, synthetic chemistry expertise, and robust in vitro testing capabilities. They also manage preclinical services, including formulation development and animal studies. RxCelerate boasts a significant international presence with operations strategically positioned within Europe and North America. The company is structured as a leading provider of outsourced drug discovery and development, emphasizing project management to ensure seamless execution and client satisfaction. Rxcelerate’s skilled workforce ensures high standards across all services. RXCelerate's SIC codes include -72110: Research and experimental development on biotechnology, representing the core industry focus.